C19-5-ene Steroids in Nature

Vitamins and Hormones

Volumn 71, Issue , 2005, Pages 263-299

  Lardy, Henry ^a   Marwah, Ashok ^a   Marwah, Padma ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16 HYDROXYDEHYDROEPIANDROSTERONE; 16-HYDROXYDEHYDROEPIANDROSTERONE; ANDROSTENEDIOL; DRUG DERIVATIVE; PRASTERONE; STEROID;

ANIMAL; CHEMISTRY; FEMALE; HEALTH STATUS; HUMAN; IMMUNITY; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANDROSTENEDIOL; ANIMALS; DEHYDROEPIANDROSTERONE; FEMALE; HEALTH STATUS; HUMANS; IMMUNITY; MALE; PROSTATIC NEOPLASMS; STEROIDS;

EID: 27744587018     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(05)71009-8     Document Type: Review

References (306)

1. Abrous N., Koehl M., Lemaire V., and Le Moal M. Stress prenatals: Effects deleteres a long terme sur la plasticite hippocampique et les functions cognatives. M/S 17 (2001) 119-121
2. 5-steroid metabolism under conditions of stress: Formation of 16α-hydroxyandrost-5-enes. Acta Endocrinol. 72 (1973) 319-329
3. Adams J., Archibald L., and Clarke C. Adrenal dehydroepiandrosterone and human mammary cancer. Cancer Res. 38 (1978) 4036-4040
4. Akwa Y., Morfin R., Robel P., and Baulieu E.-E. Neurosteroid metabolism. 7 alpha-hydroxylation of dehydroepiandrosterone and pregnenolone by rat brain microsomes. Biochem. J. 288 (1992) 959-964
5. Allen E., and Doisy E. An ovarian hormone. Preliminary report on its location, extraction and partial purification, and action in test animals. J. Am. Med. Assoc. 81 (1923) 819-821
6. Anderson R., Chambas E., Defaye G., Madani C., Baillie T., and Brooks C. Steroids in the human newborn. Lipophilic gel separation and gas phase analysis. J. Chromatogr. Sci. 12 (1974) 636-641
7. Araneo B., Dowell T., Woods M., Daynes R., Judd M., and Evans T. DHEAS as an effective vaccine adjuvant in elderly humans. Ann. N.Y. Acad. Sci. 774 (1995) 232-248
8. Arlt W., Calles F., Koehler I., vanVlijmen J., Fassnacht M., Strasburger C., Seibel M., Huebler D., Ernst M., Oettel M., Reincke M., Schulte H., and Alliolo B. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J. Clin. Endocrinol. Metabol. 86 (2001) 4686-4692
9. Arlt W. Dehydroepiandrosterone and aging. Best Practice Res. Clin. Endocrinol. Metabol. 18 (2004) 363-380
10. Aschheim B., and Zondek S. Ovum and Hormone. Clinische Wochensch. 6 (1927) 1321-1322
11. Attal-Khemis S., Dalmeyda V., Michot J.-L., Roudier M., and Morfin R. Increased total 7α-hydroxy-dehydroepiandrosterone in serum of patients with Alzheimer's disease. J. Gerontol. 53A (1998) B125-B132
12. Barrett-Connor E., Khaw K.-T., and Yen S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N. Engl. J. Med. 315 (1986) 1519-1524
13. Barrett-Connor E., and Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Ann. N.Y. Acad. Sci. 774 (1995) 259-270
14. Barrington K. Hazards of systemic steroids for ventilator-dependent preterm infants: What would a parent want?. Can. Med. Assn. J. 165 (2001) 33-34
15. Barry N., McGuire J., and van Vollenhoven R. Dehydroepiandrosterone in systemic lupus erythematosus: Relationship between dosage, serum levels and clinical response. J. Rheumatol. 25 (1998) 2352-2356
16. Bartsch W., Kozak I., Gorenflos P., Becker H., and Voight K. Concentrations of 3β-hydroxy androgens in epithelium and stroma of benign hyperplastic and normal human prostate. Prostate 8 (1986) 3-10
17. Baulieu E.-E. Studies of conjugated 17-ketosteroids in a case of adrenal tumor. J. Clin. Endocrinol. 22 (1962) 501-505
18. Baulieu E.-E. Studies on dehydroepiandrosterone (DHEA) and its sulfate during aging. C. R. Acad. Sci. Paris Life Sci. 318 (1995) 7-11
19. Baulieu E.-E. Neurosteroids: Of the nervous system, by the nervous system, for the nervous system. Rec. Prog. Horm. Res. 52 (1997) 1-32
20. Baulieu E.-E., and Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive steroids. J. Endocrinol. 150 (1996) S221-S239
21. Baulieu E.-E., Corpechot C., Dray F., Emiliozzi R., Lebeau M., Mauvis-Jarvis P., and Robel P. An adrenally-secreted "androgen": DHAS. Its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man. Recent Prog. Horm. Res. 21 (1965) 441-494
22. In: Baulieu E.-E., Robel P., and Schumacher M. (Eds). "Neurosteroids. A New Regulatory Function in the Nervous System." (1999), Humana Press, Totowa, NJ
23. Baxter J., Schambelan M., Matulich D., Spindler B., Taylor A., and Bartter F. Aldosterone receptors and the evaluation of plasma mineralocorticoid activity in normal and hypertensive states. J. Clin. Invest. 58 (1976) 579-589
24. Belanger B., Belanger A., Labrie F., Dupont A., Cusan L., and Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. J. Steroid Biochem. 32 (1989) 695-698
25. Belanger B., Couture J., Caron S., Bodou P., Fiet J., and Belanger A. Production and secretion of C-19 steroids by rat and guinea pig adrenals. Steroids 55 (1990) 360-365
26. Bellei M., Batteli D., Fornier C., Mori G., Muscatello U., Lardy H., and Bobyleva V. Changes in liver structure and function after short-term and long-term treatment of rats with dehydroepiandrosterone. J. Nutr. 122 (1992) 967-976
27. Berr C., Lafont S., Debuire B., Dartigues J.-F., and Baulieu E.-E. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: A French community-based study. Proc. Natl. Acad. Sci. USA 93 (1996) 13410-13415
28. Beyer C., Larsson K., Perez-Palacios G., and Morali G. Androgen structure and male sexual behavior in the castrated rat. Horm. Behav. 4 (1973) 99-108
29. In: Biggio G., and Purdy R. (Eds). "Neurosteroids and Brain Functions." (2001), Academic Press, San Diego, CA
30. 3,5-Androstadien-dion-(7,17). Helv. Chim. Acta 31 (1948) 629-632
31. Bird C., Tremblay J., Masters V., and Ciark A. Delta 5-androstenediol: Kinetics of metabolism and binding to plasma proteins in normal post-menopausal women. Acta Endocrinol. 99 (1982) 309-313
32. Bloch M., Schmidt P., Donaceau M., Adams L., and Rubinow D. Dehydroepiandrosterone treatment of midlife dysthymia. Biol. Psychiat. 456 (1999) 1533-1541
33. Bobyleva V., Kneer N., Bellei M., Battelli D., and Lardy H. Concerning the mechanism of increased thermogenesis in rats treated with dehydroepiandrosterone. J. Bioenergetics Biomembr. 25 (1993) 313-321
34. Bobyleva V., Kneer N., Bellei M., Battelli D., Muscatello U., and Lardy H. Comparative studies of effects of dehydroepiandrosterone on rat and chicken liver. Comp. Biochem. Physiol. 105B (1993) 643-647
35. Bobyleva V., Bellei M., Kneer N., and Lardy H. The effects of the ergosteroid 7-oxo-dehydroepiandrosterone on mitochondrial membrane potential: Possible relationship to thermogenesis. Arch. Biochem. Biophys. 341 (1997) 122-128
36. Boccuzzi G., Brignardello E., Di Monaco M., Forte C., Leonardi L., and Pizzini A. Influence of dehydroepiandrosterone and androstene-3β,17β-diol on the growth of MCF-7 human breast cancer cells induced by17β-estradiol. Anticancer Res. 12 (1992) 799-804
37. Boccuzzi G., Brignardello E., Di Monaco M., Gatto V., Leonardi L., Pizzini A., and Gallo M. 5-En-androstene-3β,17β-diol inhibits the growth of MCF-7 breast cancer cells when estrogen receptors are blocked by estradiol. Br. J. Cancer 70 (1994) 1035-1039
38. Bonney R., Scanlon M., Jones D., Beranek P., Reed M., and James V. The interrelationship between plasma 5-ene adrenal androgens in normal women. J. Steroid Biochem. 20 (1984) 1353-1355
39. Browne E., Porter J., Correa G., Abadie J., and Svec F. Dehydroepiandrosterone regulation of the hepatic glucocorticoid receptor in the Zucker rat. J. Steroid Biochem. Mol. Biol. 45 (1993) 517-524
40. Brownsey B., Cameron E., Griffiths K., Gleave E., Forrest A., and Campbell H. Plasma dehydroepiandrosterone sulfate levels in patients with benign and malignant breast cancer. Eur. J. Cancer 8 (1972) 131-137
41. Bulbrook R., Hayward J., and Spicer C. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet 2 (1971) 395-398
42. Bush I., Swale J., and Patterson J. Analysis of steroids in adrenal venous blood and in urine in a case of virilism. Biochem. J. 62 (1956) 16P-17P
43. Butenandt A. Uber "Progynon" ein krystallisiertes weibliches Sexualhormon. Naturwiss. 17 (1929) 879
44. Butenandt A. Uber die chemische untersuchung der Sexualhormone. Z. Angew. Chem. 44 (1931) 905-908
45. Butenandt A. Chemical Constitution of the follicular and testicular hormones. Nature 130 (1932) 238
46. Butenandt A. Uber die Chemie der Sexualhormone. Angew. Chem. 45 (1932) 655-656
47. Butenandt A., and Dannenbaum H. Uber Androsteron. III. Isolierung eines neuen unwirksamen Sterinderivates aus Mannerharn, seine Verknupfung mit Dehydro-androsteron und Androsteron: Ein Beitrag zur Konstitution des Androsterons. Z. Physiol. Chem. 229 (1934) 192-208
48. Butenandt A., and Tscherning K. Uber Androsteron, ein krystallisiertes mannliches Sexualhormon. I. Isolierung und Reindarstellung aus Mannerharn. Z. Physiol. Chem. 229 (1934) 167-184
49. Campbell C., Caperuto L., Hirata A., Araujo E., Velloso L., Saad M., and Carvalho C. The phosphatidylinositol/AKT/atypical PKC pathway is involved in the improved insulin sensitivity by DHEA in muscle and liver of rats in vivo. Life Sci. 76 (2004) 57-70
50. Carstensen J., Tesdorpf J., Kaufmann M., Markus M., Husen B., Leenders F., Jakob F., De Launoit Y., and Adamski J. Characterization of 17β-hydroxysteroid dehydrogenase IV. J. Endocrinol. 150 (1996) S3-S12
51. Casey M., Shackelton C., and Mac Donald P. Dehydroepiandrosterone therapeutics: Acetylation of DHA in mouse liver. J. Steroid Biochem. 30 (1988) 149-154
52. Casson P., Andersen R., Herrod H., Stentz F., Straughn A., Abraham G., and Buster J. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am. J. Obstet. Gynecol. 169 (1993) 1536-1539
53. Catalina F., Milewich L., Frawley W., Kumar V., and Bennett M. Decrease of core body temperature in mice by dehydroepiandrosterone. Exp. Biol. Med. 227 (2002) 382-388
54. 5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc. Natl. Acad. Sci. USA 96 (1999) 11173-11177
55. Chasalow F., Blethen S., Duckett D., Zeitlin S., and Greenfield J. Serum levels of dehydroepiandrosterone sulfate as determined by commercial kits and reagents. Steroids 54 (1989) 373-383
56. Chmielewski V., Drupt F., and Morfin R. Dexamethasone-induced apoptosis of mouse thymocytes: Prevention by native 7α-hydroxysteroids. Immunol. Cell. Biol. 78 (2000) 238-246
57. Chen F., Knecht K., Leu C., Rutledge S., Scafonaas A., Gambone C., Vogel R., Zhang H., Kasparcova V., Bai C., Harada S., Schmidt A., Reszka A., and Freedman L. Partial agonist/antagonist properties of androstenedione and 4-androsten-3β,17β-diol. J. Steroid Biochem. Mol. Biol. 91 (2004) 247-257
58. Cleary M., and Zisk J. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int. J. Obesity 10 (1986) 193-204
59. Cleary M., Shepherd A., Zisk J., and Schwartz A. Effect of dehydroepiandrosterone on body weight and food intake in rats. Nutrit. Behav. 1 (1983) 127-136
60. Colas A., Heinrichs W., and Tatum H. Pettenkofer chromogens in the maternal and fetal circulations: Detection of 3β,16α-dihydroxy-androst-5-en-17-one in umbilical cord blood. Steroids 3 (1964) 417-434
61. Coleman D., Leiter E., and Schwizer R. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 31 (1982) 830-833
62. Coleman D., Schwizer R., and Leiter E. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes 33 (1984) 26-32
63. vy), and normal mice. Endocrinology 117 (1985) 2279-2283
64. Corpechot C., Robel P., Axelson M., Sjovall J., and Baulieu E.-E. Characterization and measurement of dehydroepiandrosterone sulfate in the rat brain. Proc. Natl. Acad. Sci. USA 78 (1981) 4704-4707
65. Dammann O., Levuiton A., Bartels B., and Dammann C. Lung and brain damage in preterm newborns. Biol. Neonate 85 (2004) 305-313
66. Danenberg H., Ben-Yehuda A., Zakey-Rones Z., and Friedman G. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine 13 (1995) 1445-1448
67. Davidson M., Marwah A., Sawchuk R., Maki K., Marwah P., Weeks C., and Lardy H. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin. Invest. Med. 23 (2000) 300-310
68. Daynes R., and Araneo B. Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4. Eur. J. Immunol. 19 (1989) 2319-2325
69. Daynes R., and Araneo A. Prevention and reversal of some age-associated changes in immunologic responses by supplemental dehydroepiandrosterone sulfate therapy. Aging Immunol. Infect. Dis. 3 (1992) 135-154
70. Daynes R., Dudley D., and Araneo B. Regulation of murine lymphokine production in vivo II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 syntheses by helper T cells. Eur. J. Immunol. 20 (1990) 793-802
71. Deanesly R., and Parkes A. Comparative activities of compounds of the androsterone-testosterone series. Biochem. J. 3 (1936) 291-303
72. De Peretti E., and Forest M. Pattern of plasma DHAES levels in humans from birth to adulthood: Evidence for testicular production. J. Clin. Endocrinol. Metabol. 47 (1978) 572-577
73. Dhatariya K., and Nair K. Dehydroepiandrosterone: Is there a role for replacement?. Mayo Clin. Proc. 78 (2003) 1257-1273
74. Diamond P., Cusan L., Gomez J., Belanger A., and Labrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J. Endocrinol. 150 (1996) S43-S50
75. Dingemanse E., de Jongh S., Kober S., and Laqueur E. Crystalline menformone Deutsch. Med. Wochensch. 56 (1930) 301-304
76. Djerassi C., and Hoffman R. "Oxygen, a Play in Two Acts." (2001), Wiley, New York
77. Djeridane Y., and Touitou Y. Ex vivo studies on the acute and chronic effects of DHEA and DHEA-sulfate on melatonin synthesis in young and old rat pineal glands. Steroids 69 (2004) 343-349
78. Doisy E.A., Veler C., and Thayer S. Folliculin from urine of pregnant women. Am. J. Physiol. 90 (1929) 329-330
79. Doisy E., Thayer S., Levin L., and Curtis J. A new tri-atomic alcohol from the urine of pregnant women. Proc. Soc. Exp. Biol. Med. 28 (1930) 88-89
80. Doisy E.A., Veler C., and Thayer S. The preparation of the crystalline ovarian hormone from the urine of pregnant women. J. Biol. Chem. 86 (1930) 499-509
81. Dossantos R., Alfadda A., Eto K., Kadowaki T., and Silva J. Evidence for a compensated thermogenic defect in transgenic mice lacking the mitochondrial glycerol-3-phosphate dehydrogenase gene. Endocrinology 144 (2003) 5469-5479
82. Doyle L., Davis P., and Morley C. Risks and benefits of steroids in preterm infants. J. Pediat. 138 (2001) 784-785
83. Dreisbach R. The effects of steroid sex hormones on pregnant rats. J. Endocrinol. 18 (1959) 271-277
84. Dumas M., Begue R., Escousse A., and Padieu P. Steroids and hypertension: 2. Urinary excretion of 3,16-dihydroxy-17-oxosteroids in hypertension. Influence of β-adrenoceptor-blocking agents. Eur. J. Mass Spec. Biochem. Med. 2 (1982) 43-48
85. Dyner T., Lang W., Geaga J., Golub A., Stites D., Winger E., Galmarini M., Masterson J., and Jacobson M. An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J. Acquir. Immune Defic. Syndr. 6 (1993) 459-465
86. Edery M., Carreau S., Simon M., and Drosdowsky M. In vitro pregnenolone metabolism by mouse adrenal gland: II. Biosynthesis of androgens. Steroids 39 (1982) 191-200
87. Estrada-O S., Rightmire B., and Lardy H. Antibiotics as tools for metabolic studies XI. Specific inhibition of ion transport in mitochondria by the monensins. Antimicrob. Agents Chemother. (1967) 279-288
88. Fahien L., Laboy J., Din Z., Prabhaker P., Budker T., and Chobanian M. Ability of cytosolic malate dehydrogenase and lactate dehydrogenase to increase the ratio of NADPH to NADH oxidation by cytosolic glycerol-3-phosphate dehydrogenase. Arch. Biochem. Biophys. 364 (1999) 185-194
89. Farr S., Banks W., Uezu K., Gaskin F., and Morley J. DHEAS improves learning and memory in aged SAMP8 mice but not in diabetic mice. Life Sci. 75 (2004) 27756 2785
90. Flood J., Morley J., and Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc. Natl. Acad. Sci. USA 89 (1992) 1567-1571
91. Flood J., Smith G., and Roberts E. Dehydroepiandrosterone and its sulfate enhance memory retention in mice. Brain Res. 447 (1998) 269-278
92. Fotherby K., Colas A., Atherden S., and Marrian G. The isolation of 16α-hydroxydehydroepiandrosterone (3β,16α-dihydroxyandrost-5-en-17-one) from the urine of normal men. Biochem. J. 66 (1957) 664-669
93. 3H-labeled androgens to the estrogen receptor. Endocrinology 104 (1979) 1797-1804
94. Gardiner W., Brooks C., Horning E., and Hill R. Urinary steroid pattern of the human newborn infant. Biochem. Biophys. Acta 130 (1966) 278-281
95. Genazzini A., Stomati M., Bernardi F., Pieri M., Rovati L., and Genazzini A. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women. Fertil. Steril. 80 (2003) 1495-1501
96. Gomez F., Miyazaki M., Kim Y.-C., Marwah P., Lardy H., Ntambi J., and Fox B. Molecular differences caused by differentiation of 3T3-L1 preadipocytes in the presence of either dehydroepiandrosterone (DHEA) or 7-oxo-DHEA. Biochemistry 41 (2002) 5473-5482
97. Goodyear I., Park R., Netherton C., and Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br. J. Psychiatry; J. Mental Sci. 179 (2001) 243-249
98. Gordon G., Schantz L., and Talalay P. Modulation of growth, differentiation, and carcinogenesis by dehydroepiandrosterone. Adv. Enzymol. 26 (1987) 355-382
99. Gottlieb B., Beitel L.K., Wu J.-H., and Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat. 23 (2004) 527-533
100. Halliday H. Postnatal steroids: A dilemma for the neonatologist. Acta Pediatr. 90 (2001) 116-118
101. Hampl R., and Starka L. In vitro metabolic transformations of 7α-hydroxydehydroepiandrosterone in rat liver, adrenal and testis. Endocrinol. Exp. 1 (1967) 5-13
102. Hampl R., Lapcik O., Hill M., Klak J., Kasal A., Novacek A., Sterzl I., Sterzl. J., and Starka L. 7-Hydroxydehydroepiandrosterone-a natural antiglucocorticoid and a candidate for steroid replacement therapy?. Physiol. Res. 49 (2000) S107-S112
103. Harper M., Pike A., Peeling W., and Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J. Endocrinol. 60 (1974) 117-125
104. Hata T., Manabe A., Yonehara T., Aoki S., and Miyazaki K. Power Doppler enhancement of the placenta by dehydroepiandrosterone sulfate in term pregnancy. Br. J. Obstet. Gynecol. 105 (1998) 360-361
105. Heinrichs W., Feder H., and Colas A. The steroid 16α-hydroxylase system in mammalian liver. Steroids 7 (1966) 91-98
106. Hellerstedt B., Pientas K., Redman B., Esper P., Dunn R., Fardig J., Olson K., and Smith D. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer 98 (2003) 1603-1610
107. Henwood S., Weeks C., and Lardy H. An escalating dose oral gavage study of 3β-acetoxyandrost-5-ene-7,17-dione (7-oxoDHEA-acetate) in Rhesus monkeys. Biochem. Biophys. Res. Commun. 254 (1999) 124-126
108. Herbert J. Neurosteroids, brain damage, and mental illness. Exp. Gerontol. 33 (1998) 713-727
109. 5-androstenetriol-3β,16,17. Biol. Chem. 150 (1943) 363-379
110. Hirschmann H., and Hirschmann F. Steroid excretion in a case of adrenocortical carcinoma II. An examination of the non-ketonic fraction precipitable with digitonin. J. Biol. Chem. 157 (1945) 601-612
111. Hirschmann H., De Courcy C., Levy R., and Miller K. Adrenal precursors of urinary 17-ketosteroids. J. Biol. Chem. 235 (1960) PC48-PC49
112. Hirshman E., Merritt P., Wang C., Wierman M., Budescu D., Kohrt W., Templin J., and Bhasin S. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Horm. Behav. 45 (2004) 144-155
113. Hochberg R., Bandy L., Ponticorvo L., Welch M., and Lieberman S. Naturally occurring lipoidal derivatives of 3β-hydroxy-5-pregnen-20-one; 3β,17-α-dihydroxy-5-pregnen-20-one and 3β-hydroxy-5-androsten-17-one. J. Steroid Biochem. 11 (1979) 1333-1340
114. Homoki J., Roitman E., and Shackelton C. Characterization of the major steroids present in amniotic fluid obtained between the 15th and 17th weeks of gestation. J. Steroid Biochem. 19 (1983) 1061-1068
115. Huggins C. The physiology of the prostate gland. Physiol. Rev. 25 (1945) 281-295
116. Huggins C., and Hodges C. Studies on prostate cancer: I. The effect of castration, of oestrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1 (1941) 292-297
117. Huggins C., and Scott W. Bilateral adrenalectomy in prostate cancer. Ann. Surg. Vol. 122 (1945) 1031-1041
118. 19 steroids in adult human urine. Steroids 14 (1969) 235-250
119. Jaquish C., Blangero J., Haffner S., Stern M., and MacCluer J. Quantitative genetics of dehydroepiandrosterone sulfate and its relation to possible cardiovascular disease risk factors in Mexican Americans. Hum. Hered. 46 (1996) 301-309
120. Jo H., Ahn H., Kim E., Kim H., Seong S., Lee I., and Lee M. Effects of dehydroepiandrosterone on articular cartilage during the development of osteoarthritis. Arthrit. Rheumat. 50 (2004) 2531-2538
121. Kahn A., and Halloran B. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. J. Clin. Endocrinol. Metabol. 87 (2002) 1544-1549
122. 3H] DHEA binding in rat liver. Biochem. Biophys. Res. Commun. 156 (1988) 22-29
123. In: Kalimi M., and Regelson W. (Eds). "The Biologic Role of Dehydroepiandrosterone (DHEA)." (1990), De Gruyter, New York
124. In: Kalimi M., and Regelson W. (Eds). "Dehydroepiandrosterone (DHEA): Biochemical, Physiological, and Clinical Aspects." (2000), De Gruyter, Berlin
125. Kalimi M., Shafagoj Y., Loria R., Padgett D., and Regelson W. Ant-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol. Cell. Biochem. 131 (1994) 99-104
126. Kalman D., Colker C., Swain M., Torina G., and Shi Q. A randomized, double blind, placebo controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight adults. Curr. Ther. Res. 61 (2000) 435-442
127. Kask E. 17-Ketosteroids and arteriosclerosis. Angiology 10 (1959) 358-368
128. Kay H., Bird. I., Coe C., and Dudley D. Antenatal steroid treatment and adverse fetal effects: What is the evidence?. Soc. Gynecol. Investig. 7 (2000) 269-278
129. Kazihnitkova H., Tejkalova H., Benesova O., Bicikova M., Hill M., and Hampl R. Simultaneous determination of dehydroepiandrosterone, its 7-hydroxylated metabolites and their sulfates in rat brain tissues. Steroids 69 (2004) 667-674
130. Khalil M., Strutt B., Vachon D., and Killinger D. Effect of dexamethasone and cytochrome P450 inhibitors on the formation of 7α-hydroxydehydroepiandrosterone by human adipose stromal cells. J. Steroid Biochem. Mol. Biol. 48 (1994) 545-552
131. Khan N., Sharma K., Anderson S., and Auchus R. Human 17β-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells. Arch. Biochem. Biophys. 429 (2004) 50-59
132. Khorram O., Vu L., and Yen S. Activation of immune function by dehydroepiandrosterone (DHEA) in age advanced men. J. Gerontol. 71 (1997) 695-704
133. Kimonides V., Khatibi N., Svendsen C., Sofroniew M., and Herbert J. Dehydroepiandrosterone and DHEA-sulfate protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 95 (1998) 1852-1857
134. Kimonides V., Spillantini M., Sofroniew M., Fawcett J., and Herbert J. Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in primary hippocampal cultures. Neuroscience 89 (1999) 429-436
135. Kline M., and Jaggers E. Mania onset while using dehydroepiandrosterone. Am. J. Psychiat. 156 (1999) 971
136. Kneer N., and Lardy H. Thyroid hormone and dehydroepiandrosterone permit gluconeogenic hormone responses in hepatocytes. Arch. Biochem. Biophys. 375 (2000) 145-153
137. 5-androstenediol on castrated and ovariectomized rats. Biochem. J. 31 (1937) 467-474
138. Koshland D. Mechanisms of transfer enzymes. In: Boyer P., Lardy H., and Myrback K. (Eds). "The Enzymes" 1 (1959) 305-346
139. Kritchevsky D., Teppoer S., Klurfeld D., and Schwartz A. Influence of dehydroepiandrosterone (DHEA) on cholesterol metabolism in rats. Pharmacol. Res. Commun. 15 (1983) 797-803
140. Kurzman I., Mac Ewen E., and Haffa A. Reduction in body weight and cholesterol in spontaneously obese dogs by dehydroepiandrosterone. Int. J. Obesity 14 (1990) 95-204
141. Labrie F., Diamond P., Cusan L., Gomez J.-L., Belanger A., and Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metabol. 82 (1997) 3498-3505
142. Labrie F., Belanger A., Luu-The V., Labrie C., Simard J., Cusan L., Gomez J.-L., and Candas B. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging. Steroids 63 (1998) 322-328
143. Labrie F., Luu-The V., Lin S., Simard J., Labrie C., El-Alfy M., Pelletier G., and Belanger A. Intracrinology: Role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 25 (2000) 1-16
144. Lardy H., Henwood S., and Weeks C. An acute oral gavage study of 3β-acetoxyandrost-5-ene-7,17-dione (7-oxoDHEA-acetate) in rats. Biochem. Biophys. Res. Commun. 254 (1999) 120-123
145. Lardy H., Kneer N., Wei Y., Partridge B., and Marwah P. Ergosteroids, II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 63 (1998) 158-165
146. Lardy H., Marwah A., and Marwah P. Transformations of DHEA and its metabolites by rat liver. Lipids 37 (2002) 1187-1191
147. Lardy H., Paetkau V., and Walter P. Paths of carbon in gluconeogenesis and lipogenesis: The role of mitochondria in supplying precursors of phosphoenolpyruvate. Proc. Natl. Acad. Sci. USA 53 (1965) 1410-1415
148. Lardy H., Partridge B., Kneer N., and Wei Y. Ergosteroids: Iinduction of thermogenic enzymes in livers of rats treated with steroids derived from dehydroepiandrosterone. Proc. Natl. Acad. Sci. USA 92 (1995) 6617-6619
149. Lardy H., Su C.-Y., Kneer N., and Wielgus S. Dehydroepiandrosterone induces enzymes that permit thermogenesis and decrease metabolic efficiency. In: Lardy H., and Stratman F. (Eds). "Hormones, Thermogenesis, and Obesity" (1989), Elsevier, New York 415-426
150. Laurine E., Lafitte D., Gregoire C., Seree E., Loret E., Douillard S., Michel B., Briand C., and Verdier J.-M. Specific binding of dehydroepiandrosterone to the N terminus of the microtubule-associated protein MAP2. J. Biol. Chem. 278 (2003) 29979-29986
151. Lee Y.-P., and Lardy H. Influence of thyroid hormones on L-α-glycerophosphate dehydrogenase and other dehydrogenases in various organs of the rat. J. Biol. Chem. 240 (1965) 1427-1436
152. Lee Y.-P., Takemori A., and Lardy H. Enhanced oxidation of α-glycerophosphate by mitochondria of thyroid-fed rats. J. Biol. Chem. 234 (1959) 3051-3054
153. scc in rat brain. Science 237 (1987) 1212-1214
154. Legrain S., and Girard L. Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects. Drugs Aging 20 (2003) 949-967
155. Leighton B., Tagliaferro A., and Newsholme E. The effect of dehydroepiandrosterone acetate on liver peroxisomal enzyme activities of male and female rats. J. Nutrit. 117 (1987) 1287-1290
156. Lejeune-Lenain C., Van Cauter E., Desir D., Beyloos M., and Franckson J. Control of circadian and episodic variations of adrenal androgens secretion in man. J. Endocrinol. Invest. 10 (1987) 267-276
157. Liddle G., and Sennett J. New mineralocorticoids in the syndrome of low-renin essential hypertension. J. Steroid Biochem. 6 (1975) 751-753
158. Lieberman S., Dobriner K., Hill B., Fieser L., and Rhoads C. Studies on steroid metabolism II. Identification and characterization of ketosteroids isolated from urine of healthy and diseased persons. J. Biol. Chem. 172 (1948) 263-295
159. Lieberman S. An abbreviated account of some aspects of the biochemistry of DHEA, 1934-1995. Ann. N. Y. Acad. Sci. 774 (1995) 1-15
160. Lieberman S., and Prasad V. Heterodox notions on pathways of steroidogenesis. Endocrine Rev. 11 (1990) 469-493
161. Liere P., Akwa Y., Weill-Engerer S., Eychenne B., Pianos A., Robel P., Sjovall J., Schumacher M., and Baulieu E.-E. Validation of an analytical procedure to measure trace amounts of neurosteroids in brain tissue by gas chromatography-mass spectrometry. J. Chromatog. B 739 (2000) 301-312
162. Liggins G.C., and Howie R.N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 50 (1972) 515-525
163. Loewe H., Voss H., Lange F., and Wahner A. Sexualhormon befunde im Mannlichen harn. Klin. Wochenschr. 7 (1928) 1376-1377
164. Loria R., and Padgett D. Androstenediol regulates systemic resistance against lethal infections in mice. Arch. Virol. 127 (1992) 103-115
165. Loria R., Inge T., Cook S., Szakal A., and Regelson W. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J. Med. Virol. 26 (1988) 301-314
166. Lovas K., Gebre-Medhin G., Trovik T., Fougner K., Uhlving S., Nedrebo B., Myking O., Kampe O., and Husebye E. Replacement of dehydroepiandrosterone in adrenal failure: No benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J. Clin. Endocrinol. Metabol. 88 (2003) 1112-1118
167. A receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38 (1992) 279-295
168. Majewska M. Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory and affect. Ann. N.Y. Acad. Sci. 774 (1995) 111-120
169. Mason H., and Kepler E. Urinary steroids isolated after administration of dehydroisoandrosterone to human subjects. J. Biol. Chem. 167 (1947) 73-76
170. Marrian G. Chemistry of estrin. III. An improved method of preparation and the isolation of active crystalline material 24 (1930) 435-445
171. 5-androstene-3β,16,17-triol from the urine of normal human males and females. Biochem. J. 38 (1944) 322-324
172. Martel C., Sourla A., Pelletier G., Labrie C., Fournier M., Picard S., Li S., Stojanovic M., and Labrie F. Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol. 157 (1998) 433-442
173. Martin C., Bean R., Rose K., Habib F., and Seckl J. CYP7b 1 Catalyzes the 7α-hydroxylation of dehydroepiandrosterone and 25-hydroxycholesterol in rat prostate. Biochem. J. 355 (2001) 509-515
174. Marwah A., Marwah P., and Lardy H. High-performance liquid chromatographic analysis of dehydroepiandrosterone. J. Chromatog. A 935 (2001) 279-296
175. Marwah A., Marwah P., and Lardy H. Ergosteroids VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: A liquid chromatographic-mass spectrometric study. J. Chromatog. B 767 (2002) 285-299
176. Matsunaga M., Ukena K., Baulieu E.-E., and Tsutsui K. 7α-Hydroxypregnenolone acts as a novel neuronal activator to stimulate locomotor activity of breeding newts via the dopaminergic system. Proc. Natl. Acad. Sci. USA 101 (2004) 17282-17287
177. Maunther J., and Suida W. Beitrage zur Kenntniss des Cholesterins. Monatsheft Chem. 17 (1896) 579-603
178. May M., Holmes E., Rogers W., and Poth M. Protection from glucocorticoid induced thymic involution by dehydroepiandrosterone. Life Sci. 46 (1991) 1627-1631
179. McEwen B. Protective and damaging effects of stress mediators: The good and bad sides of the response to stress. Metabol. Clin. Exp. 51 (2002) 2-4
180. McIntosh M., Pan J.-S., and Berdanier C. In vitro studies on the effects of dehydroepiandrosterone and corticosterone on hepatic steroid receptor binding and mitochondrial respiration. Comp. Biochgem. Physiol. 104A (1993) 147-153
181. Meikle A., Dorchuck R., Araneo B., Stringham J., Evans T., Spruance S., and Daynes R. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J. Steroid Biochem. Mol. Biol. 42 (1992) 293-304
182. Migeon C., Keller A., Lawrence B., and Shepard T. Dehydroepiandrosterone and androsterone levels in human plasma. Effect of age and sex; day-to-day and diurnal variations. J. Clin. Endocrinol. Metabol. 17 (1957) 1051-1062
183. Milewich L., Catalina F., and Bennett M. Pleotropic effects of dietary DHEA. Ann. N. Y. Acad. Sci. 774 (1995) 149-170
184. Miller K., Cai J., Ripp S., Pierce W., Rushmore T., and Prough R. Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metabol. Disposition 32 (2004) 305-313
185. Mitamura K., Nakagawa T., Shimada K., Namiki M., Koh E., Mizokami A., and Honma S. Identification of dehydroepiandrosterone metabolites formed from human prostate homogenate using liquid chromatography-mass spectrometry and gas chromatography-mass spectroscopy. J. Chromatog. A 961 (2002) 97-105
186. Miyamoto H., Marwah P., Marwah A., Lardy H., and Chang C. 3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc. Natl. Acad. Sci. USA 100 (2003) 4440-4444
187. 5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc. Natl. Acad. Sci. USA 95 (1998) 11083-11088
188. Miyamoto H., Marwah P., Yang Z., Chang H.-C., Lardy H., and Chang C. Identification of dehydroepiandrosterone derivatives that function as potent antiandrogens. Int. J. Cancer 117 (2005) in press.
189. Mizokami A., Koh E., Fujita H., Aeda Y., Egawa M., Koshida K., Honma S., Keller E., and Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 64 (2004) 765-771
190. Mohan P., Ihnen J., Levin B., and Cleary M. Effects of dehydroepiandrosterone treatment in rats with diet-induced obesity. J. Nutr. 120 (1990) 1103 111
191. Monder C. The forms and functions of 11 beta-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 45 (1993) 161-165
192. Morales A., Nolan J., Nelson J., and Yen S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metabol. 78 (1994) 1360-1367
193. Morfin R., and Courchay G. Pregnenolone and dehydroepiandrosterone as precursors of native 7-hydroxylated metabolites, which increase the immune response in mice. J. Steroid Biochem. Mol. Biol. 50 (1994) 91-100
194. Morgan C., Southwick S., Hazlett G., Rasmusson A., Hoyt G., Zimolo Z., and Charney D. Relationships among plasma dehydroepiandrosterone sulfate and cortisol levels, symptoms of dissociation, and objective performance in humans exposed to acute stress. Arch. Gen. Psychiat. 61 (2004) 819-825
195. Mulder J., Frissen P., Krijnen P., Endert E., de Wolf F., Goudsmit J., Masterson J., and Lange J. Dehydroepiandrosterone as predictor for progression to Aids in asymptomatic human immunodeficiency virus-infected men. J. Infect. Dis. 165 (1992) 413-418
196. Muller-Hill B. Hidden history. Nature 431 (2004) 246
197. Munson P., Gallgher T., and Koch F. Isolation of dehydroisoandrosterone sulfate from normal male urine. J. Biol. Chem. 152 (1944) 67-77
198. Nafziger A., Herrington D., and Bush T. Dehydroepiandrosterone and dehydroepiandrosterone sulfate: Their relation to cardiovascular disease. Epidemiol. Rev. 13 (1991) 267-293
199. Nasman B., Olsson T., Seckl J., Eriksson S., Viitanen M., Bucht G., and Carlstrom K. Abnormalities in adrenal androgens, but not of glucocorticoids, in early Alzheimer's disease. Psychoneuroendocrinology 20 (1995) 83-94
200. Navarro D., Luzardo O., Fernandez L., Chesa N., and Diaz-Chico B. Transition to androgen-independence in prostate cancer. J. Steroid Biochem. Mol. Biol. 81 (2002) 191-202
201. Nestler J., Barlascini C., Clore J., and Blackard W. Dehydroepiandrosterone reduces serum low-density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J. Clin. Endocrinol. Metabol. 66 (1988) 57-61
202. Neville A., and Webb J. The in vitro formation of 3β-hydroxyandrost-5-ene-7,17-dione by human adrenal glands. Steroids 6 (1965) 421-426
203. Nowaczynski W., Messerli F., Kuchel O., Guthrie G., Gordon P., and Genest J. Origin of urinary 16β-hydroxydehydroepiandrosterone in essential hypertension. J. Clin. Endocrinol. Metabol. 44 (1977) 629-638
204. Okabe T., Haji M., Takayanagi R., Adachi M., Imasaki K., Kurimoto F., Watanabe T., and Nawata H. Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J. Clin. Endo. Metabol. 80 (1995) 2993 2929
205. 5-steroids in adrenal carcinoma. J. Biol. Chem. 234 (1959) 1688-1692
206. Orentreich N., Brind J., Rizer R., and Vogelman J. Age changes and sex differences in serum DHAES concentrations throughout adulthood. J. Clin. Endocrinol. Metabol. 59 (1984) 551-555
207. Padgett D., Loria R., and Sheridan J. Steroid hormone regulation of immunity. Ann. N.Y. Acad. Sci. 917 (2000) 935-943
208. Parker L. "Adrenal Androgens in Clinical Medicine." (1989), Academic Press, San Diego
209. Pauza D., and Lardy H. Use of delta-5 androstenes in the treatment of HIV wasting syndrome (1999) U.S. Patent 5,885,977.
210. Percheron G., Hogrel J., Denot-Ledunois S., Fayet G., Forette F., Baulieu E.E., Fardeau M., and Marini J. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area-a double-blind placebo-controlled trial. Arch. Intern. Med. 163 (2003) 720-727
211. Peters J., Zhou Y.-C., Ram P., Lee S., Gonzalez F., and Waxman D. Peroxisome proliferators-activated receptor α required for gene induction by dehydroepiandrosterone-3β-sulfate. Molc. Pharmacol. 50 (1996) 67-74
212. Pincus G., Romanoff L., and Carlo J. Variations with age in neutral steroid excretion by men. Fed. Proc. 7 (1948) 93-94
213. Pincus G., Romanoff L., and Carlo J. The excretion of urinary steroids by men and women of various ages. J. Gerontol. 9 (1954) 113-132
214. 5-androstene-3β,17β-diol with estradiol and dihydrotestosterone in human myometrial and mammary cancer. J. Clin. Endocrinol. Metabol. 40 (1975) 373-378
215. 5-sex steroids to long-chain fatty acids in the ZR-75-1 human breast cancer cell line. J. Biol. Chem. 264 (1989) 9335-9343
216. Rabkin J., Ferrando S., Wagner G., and Rabkin R. DHEA treatment for HIV+ patients: Effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 25 (2000) 53-68
217. Ratko T., Detrisac C., Metha R., Kelloff G., and Moon R. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analog of dehydroepiandrosterone. Cancer Res. 51 (1991) 481-486
218. Reich I., Lardy H., Wei Y., Partridge B., Marwah P., Kneer N., Powell D., and Reich H. Ergosteroids III: Synthesis and biological activity of seco-steroids related to dehydroepiandrosterone. Steroids 63 (1998) 542-553
219. Reich I., Reich H., Kneer N., and Lardy H. Ergosteroids V: Preparation and biological activity of various D-ring derivatives in the 7-oxo-dehydroepiandrosterone series. Steroids 67 (2002) 221-233
220. Reuter S., and Mayer D. Transport of dehydroepiandrosterone and dehydroepiandrosterone sulfate into rat hepatocytes. J. Steroid Biochem. Mol. Biol. 54 (1995) 227-235
221. Reynolds J. Excretion of 16α-hydroxy steroids by premature infants. J. Clin. Endocrinol. Metabol. 26 (1966) 1251-1256
222. Reynolds J., Mancuso S., Wiqvist N., and Diczfalusy E. Studies on the aromatization of neutral steroids in pregnant women. 7. Aromatization of 3β,17β-dihydroxyandrost-5-ene-16-one by placentas perfused in situ at midpregnancy. Acta Endocrinol. 58 (1968) 377-395
223. Ricketts M., Shoesmith K., Hewison M., Strain A., and Eggo M. Regulation of 11β-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J. Endocrinol. 156 (1998) 159-168
224. Riley V. Psychoneuroendocrine influences on immunocompetence and neoplasia. Science 212 (1983) 1100-1109
225. Roberts E., Bologa L., Flood J., and Smith G. Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain Res. 406 (1987) 357-362
226. Rose D., Stauber P., Thiel A., Crawley J., and Milbrath J. Plasma dehydroepiandrosterone sulfate, androstenedione and cortisol, and urinary free cortisol excretion in breast cancer. Eur. J. Cancer 13 (1977) 43-47
227. Rose K., Stapleton G., Dott K., Kieny M., Best R., Schwarz M., Russell D., Bjorkhem I., Seckl J., and Lathe R. Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7α-hydroxy dehydroepiandrosterone and 7α-hydroxy pregnenolone. Proc. Natl. Acad. Sci. USA 94 (1997) 4925-4930
228. Rosenfeld R., Hellman L., Roffwarg H., Weitzman E., Fukushima D., and Gallagher T. Dehydroisoandrosterone is secreted episodically and synchronously with cortisol by normal men. J. Clin. Endocrinol. 33 (1971) 87-92
229. Rotter J., Wong F., Lifrak E., and Parker L. A genetic component to the variation of dehydroepiandrosterone sulfate. Metabolism 34 (1985) 731-736
230. 5-androstene-3β,16α,17β-triol to estriol by human placenta. Endocrinology 63 (1958) 392-394
231. Ryan K. Metabolism of C-16-oxygenated steroids by human placenta: The formation of estriol. J. Biol. Chem. 234 (1959) 2006-2008
232. Sakuma M., Yamada J., and Suga T. Comparison of inducing effects of dehydroepiandrosterone on hepatic peroxisome proliferation-associated enzymes in several rodent species. Biochem. Pharmacol. 43 (1992) 1269-1273
233. Salek F., Bigos K., and Kroboth P. The influence of hormones and pharmaceutical agents on DHEA and DHEAS concentrations: A review of clinical studies. J. Clin. Pharmacol. 42 (2002) 247-266
234. Salvadori B., Benassi L., Merialdi A., Coppola F., Pini L., and Cacciatore A. Feto-neonatal hormonology in premature delivery. J. Steroid Biochem. 8 (1977) 385-386
235. Samuels L. Effect of aging on the steroid metabolism as reflected in plasma levels. In: Engle E., and Pincus G. (Eds). "Hormones and the Aging Process" (1956), Academic Press, New York 1-33
236. Schneider J., and Lewbart M. Fractionation and isolation of steroid conjugates. Rec. Prog. Horm. Res. 15 (1959) 201 30
237. 5 androstene-3β,16β,17α-triol following the incubation of dehydroepiandrosterone with surviving rabbit liver slices. J. Biol. Chem. 172 (1948) 771-782
238. vy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res. 39 (1979) 1129-1132
239. Schwartz A., and Tannen R. Inhibition of 7,12-diumethylbenzanthrace and urethane-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone. Carcinogenesis 2 (1981) 1335-1337
240. Schulz S., Klann R., Schonfield S., and Nyce J. Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: Role of isoprenoid biosynthesis. Cancer Res. 52 (1992) 1372-1376
241. Sekihara H., Sennet J., Liddle G., McKenna T., and Yarbro L. Plasma 16β-hydroxydehydroepiandrosterone in normal and pathological conditions in man. J. Clin. Endocrinol. Metabol. 43 (1976) 1078-1083
242. Sennett J., Yarbro L., Slaton P., Hollifield J., and Liddle G. The C19-mineralocorticoids in hypertension. Circul. Res. 41 (1977) 260-264
243. Shackelton C., Kelly R., Adhikary P., Brooks C., Harkness R., Sykes P., and Mitchell F. The identification and measurement of a new steroid 16β-hydroxydehydroepiandrosterone in infant urine. Steroids 12 (1968) 705-716
244. Shackleton C., Gustafsson J.-A., and Sjovall J. Steroids in newborns and infants: Identification of steroids in urine from newborn infants. Steroids 17 (1971) 265-280
245. Shackelton C., Gustafsson J.-A., and Mitchell F. Steroids in newborns and infants: The changing pattern of urinary steroid excretion during infancy. Acta Endocrinol. 74 (1973) 157-167
246. Shafagoj Y., Opoku J., Qureshi D., Regelson W., and Kalimi M. Dehydroepiandrosterone prevents dexamethasone-induced hypertension in rats. Am. J. Physiol. 263 (1992) E210-E213
247. Shi J., Schulze S., and Lardy H. The effect of 7-oxo-DHEA acetate on memory in young and old C57BL/6 mice. Steroids 65 (2000) 124-129
248. 3H) pregnen-20-one by the microsomal fraction. J. Biol. Chem. 253 (1978) 4237-4245
249. Siegel D. Two independent approaches to "Kirchhoff's Radiation Law.". Isis 67 (1976) 565-600
250. 19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs. J. Steroid Biochem. 26 (1987) 539-546
251. Skolnick A. Scientific verdict still out on DHEA. JAMA 276 (1996) 1365-1368
252. Slaunwhite W., Karsay M., Hollmer A., Sandberg A., and Niswander K. Fetal liver as an endocrine tissue. Steroids 6 (1965) 211-221
253. Smith G.V., and Smith O.W. Internal secretions and toxemia of late pregnancy. Physiol. Rev. 28 (1948) 1-22
254. Solomon S. Formation and metabolism of neutral steroids in the human placenta or fetus. J. Clin. Endocrinol. Metabol. 26 (1966) 762-772
255. Sonka J. "Dehydroepiandrosterone Metabolic Effects." (1976), Universita Karlova, Praha
256. Sourla A., Flamand M., Belanger A., and Labrie F. Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat. J. Steroid Biochem. Mol. Biol. 66 (1998) 137-149
257. A receptor complex. Pharm. Exp. Ther. 282 (1997) 827-833
258. Starka L., and Kutova J. 7-Hydroxylation of dehydroepiandrosterone by rat liver homogenate. Biochim. Biophys. Acta 56 (1962) 76-82
259. Starka L., Hill M., Hampl R., Malewiak M., Benalycherif A., Morfin R., Kolena J., and Scsukova S. Studies of the mechanism of antiglucocorticoid action of 7α-hydroxydehydroepiandrosterone. Coll. Czech. Chem. Commun. 63 (1998) 1683-1698
260. Sterzl I., Hampl R., Sterzl J., Votruba J., and Starka L. 7 beta-OH-DHEA counteracts dexamethasone induced suppression of primary immune response in murine spleenocytes. J. Ster. Biochem. Mol. Biol. 71 (1999) 133-137
261. Su C.-Y., and Lardy H. Effect of dehydroepiandrosterone on mitochondrial glycerophosphate dehydrogenase and malic enzyme activities. FASEB J. 2 (1988) A511
262. Su C.-Y., and Lardy H. Induction of hepatic mitochondrial glycerophosphate dehydrogenase in rats by dehydroepiandrosterone. J. Biochem. (Tokyo) 110 (1991) 207-213
263. Sulcova J., and Starka L. Extrahepatic 7α-hydroxylation of dehydroepiandrosterone. Experimentia XIX (1963) 632-633
264. Sulcova J., Capkova A., Jirasek J., and Starka L. 7-hydroxylation of dehydroepiandrosterone in human foetal liver, adrenals and chorion in vitro. Acta Endocrinol. 59 (1968) 1-9
265. Suzuki T., Suzuki R., and Daynes R. Dehydroepiandrosterone enhances IL-2 production and cytotoxic effector function of human T-cells. Clin. Immunol. Immunopathol. 61 (1991) 202-211
266. Suzuki M., Wright L., Marwah P., Lardy H., and Svendsen C. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc. Natl. Acad. Sci. USA 101 (2004) 3202-3207
267. Svec F., and Lopez S. Antiglucocorticoid actions of dehydroepiandrosterone and low concentrations in Alzheimer's disease. Lancet 2 (1989) 1335-1336
268. Svec F., and Porter J. Dehydroepiandrosterone: A nutritional supplement with actions in the central nervous system. Nutrit. Neurosci. 1 (1998) 9-19
269. Swierczynski J., and Meyer D. Dehydroepiandrosterone-induced lipid peroxidation in rat liver mitochondria. J. Steroid Biochem. Mol. Biol. 58 (1996) 599-603
270. 5-steroids during the early neonatal period. Biol. Pharm. Bull. 20 (1997) 1295-1299
271. Tagawa N., Hidaka Y., Takano T., Shimaoka Y., Kobayashi Y., and Amino N. Serum concentrations of androstenediol and androstenediol sulfate, and their relation to cytokine production during and after normal pregnancy. Steroids 69 (2004) 675-680
272. Tagliaferro A., Davis J., Truchon S., and Van Hamont N. Effects of dehydroepiandrosterone acetate on metabolism, body weight, and composition of male and female rats. J. Nutr. 116 (1986) 1977-1983
273. Tchernof A., and Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: A review of human studies. Eur. J. Endocrinol. 151 (2004) 1-14
274. Tepperman H., and Tepperman J. Patterns of dietary and hormonal induction of certain NADP-linked liver enzymes. Am. J. Physiol. 206 (1964) 357-361
275. Thijssen J., Portman J., and Schwarz F. Androgens in postmenopausal breast cancer: Excretion, production, and interaction with estrogens. J. Ster. Biochem. 6 (1975) 729-734
276. Trivedi D., and Khaw K. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J. Clin. Endocrinol. Metabol. 86 (2001) 4171-4177
277. Tzung K.W., Ishimura-Oka K., Kihara S., Oka K., and Chan L. Structure of the mouse cholesterol 7α-hydroxylase gene. Genomics 21 (1994) 244-247
278. Usiskin K., Butterworth S., Clore J., Arad Y., Ginsberg H., Blackard W., and Nestler J. Lack of effect of dehydroepiandrosterone in obese men. Internat. J. Obesity 14 (1990) 457-463
279. Vaitukaitis J., Dale S., and Melby J. Role of ACTH in the secretion of free dehydroepiandrosterone and its sulfate ester in man. J. Clin. Endocrinol. 29 (1969) 1443 1414
280. Valle L., Toffolo V., Vianello S., Belvedere P., and Colombo L. Expression of cytochrome P450c17 and other steroid-converting enzymes in the rat kidney throughout the life span. J. Steroid Biochem. Mol. Biol. 91 (2004) 49-58
281. Vande Wiele R., Mac Donald P., Gurpide E., and Lieberman S. Studies of the secretion and interconversion of the androgens. Recent Prog. Horm. Res. 19 (1963) 275-305
282. Van Doorn L., Berenschot-Roozendaal J., Poortmen J., Thijssen J., and Schwarz F. Binding characteristics of 5-androstene-3β,17β-diol and estradiol-17β to the cytoplasmic estrogen receptor of the immature rat uterus. J. Steroid Biochem. 16 (1982) 661-671
283. van Weerden W., Bierings H., van Steenbrugge G., de Jong F., and Schroder F. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci. 50 (1992) 857-861
284. van Vollenhoven, Engleman E., and McGuire J. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthrit. Rheum. 37 (1994) 1305-1310
285. Varet J., Vincent L., Akwa Y., Mirshahi P., Lahary A., Legrand E., Opolone P., Mishal Z., Baulieu E.-E., Soria J., Soria C., and Li H. Dose-dependent effect of dehydroepiandrosterone, but not of its sulfate ester, on angiogenesis. Eur. J. Pharmacol. 502 (2004) 21-30
286. Veech R., Eggleston L., and Krebs H. The redox state of free nicotinamide-adenine dinucleotide phosphate in the cytoplasm of rat liver. Biochem. J. 115 (1969) 609-619
287. Veler C., Thayer S., and Doisy E.A. The preparation of the crystalline follicular ovarian hormone: Theelin. J. Biol. Chem. 87 (1930) 357-371
288. Vermeulen A. Adrenal androgens and aging. In: Genazzani A., Thijssen J., and Siiteri P. (Eds). "Adrenal Androgens" (1980), Raven Press, New York 207-217
289. Villareal D., and Holloszy J. Effect of DHEA on abdominal fat and insulin action in elderly women and men. A randomized controlled trial. JAMA 292 (2004) 2243-2248
290. Villareal D., Holloszy J., and Kohrt W. Effect of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin. Endocrinol. 53 (2000) 561-568
291. Villette J., Bourin P., Doinel C., Mannsour I., Fiet J., Boudou P., Dreux C., Roue R., Deboird M., and Levi F. Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J. Clin. Endocrinol. Metabol. 70 (1990) 572-577
292. Vogiatzi M., Boeck M., Vlachopapadopoulou E., El-Rachid R., and New M. Dehydroepiandrosterone in morbidly obese adolescents: Effects on weight, body composition, lipids, and insulin resistance. Metabolism 45 (1996) 1011-1115
293. Vranic M., Miles P., Rastogi K., Yamatani K., Shi Z., Lickley L., and Hetenti G. Effect of stress on glucoregulation in physiology and diabetes. Adv. Exp. Med. Biol. 291 (1991) 161-183
294. Welle S., Jozefowitz R., and Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J. Clin. Endocrinol. Metabol. 71 (1990) 1259-1264
295. Williams M., Dawood T., Ling S., Dai A., Lew R., Myles K., Funder J., Sudhir K., and Komesaroff P. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J. Clin. Endocrinol. Metabol. 89 (2004) 4708-4715
296. Wolf O. HPA axis and memory. Res. Clin. Endocrinol. Metabol. 17 (2003) 287-299
297. Wolthers B., and Kraan G. Clinical applications of gas chromatography and gas chromatography-mass spectrometry of steroids. J. Chromatog. A 843 (1999) 247-274
298. Woodbury D. Relation between the adrenal cortex and the central nervous system. Pharmacol. Rev. 10 (1958) 275-357
299. Yamazaki T., Nawa K., Kominami S., and Takemori S. Cytochrome P-450(17alpha lyase)-mediating pathway of androgen synthesis in bovine adrenocortical cultured cells. Biochem. Biophys. Acta 1134 (1992) 143-148
300. Yen S.S.C. Dehydroepiandrosterone sulfate and longevity: New clues for an old friend. Proc. Natl. Acad. Sci. USA 98 (2001) 8167-8169
301. av/a mice by dehydroepiandrosterone. Lipids 12 (1977) 409-413
302. Young-Lai E., and Solomon S. The in vivo metabolism of 16α hydroxydehydroisoandrosterone in man. Biochemistry 6 (1967) 2040-2052
303. Young-Lai E., and Solomon S. The in vivo metabolism of 16α-hydroxylated steroids in late pregnancy. Biochemistry 7 (1968) 1881-1888
304. Zegarra-Moro O., Schmidt L., Huang H., and Tindall D. Disruption of androgen receptor function inhibits proliferation of androgen refractory prostate cancer cells. Cancer Res. 62 (2002) 1008-1013
305. Zenk J., Helmer T., Kassen L., and Kuskowski M. The effect of 7-keto Naturalean on weight loss: A randomized, double blind placebo-controlled trial. Curr. Ther. Res. 63 (2002) 263-272
306. Zumhoff B., Levin J., Rosenfeld R., Markham M., Strain G., and Fukushima D. Abnormal 24-Hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res. 41 (1981) 3360-3363